AGENUS INC

Investors weigh Agenus Inc.’s promising Phase‑2 NEOASIS results against a sharp stock decline and thin liquidity, questioning whether the biotech’s immunotherapy breakthrough can justify its current valuation.

Explore Agenus Inc. (AGEN) trading: a 1.72% uptick to $6.51, near its 200‑day MA, and context among biopharma peers—gain insights into market dynamics and growth potential.

Explore Agenus Inc. stock: current price, 52‑week high/low, and performance vs biotech peers—valuable data for investors in immuno‑oncology.

Explore why Agenus (AGEN) briefly surged yet remains fraught with long‑term doubts—thin liquidity, steep decline, and weak fundamentals make it a cautious pick.